Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that ...
BioNTech SEJanuary 20, 2021 GMT
New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an
in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01. The results were published on the preprint server bioRxiv and submitted to a peer-reviewed journal.